$MEDE
Medies

2023 Q2 Form 10-Q Financial Statement

#000168316823004915 Filed on July 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $6.160K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.947K $1.947K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $6.164K $9.939K
YoY Change -37.98%
Operating Profit -$6.164K -$9.939K
YoY Change -37.98%
Interest Expense $172.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$172.00
YoY Change
Pretax Income -$6.336K -$9.939K
YoY Change -36.25%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.336K -$9.939K
YoY Change -36.25%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 6.667M shares 4.000M shares
Diluted Shares Outstanding 6.667M shares 4.000M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $850.00
YoY Change
Cash & Equivalents $850.00 $1.862K $400.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $850.00 $1.862K
YoY Change 365.5%
LONG-TERM ASSETS
Property, Plant & Equipment $28.78K $30.73K
YoY Change -20.22%
Goodwill
YoY Change
Intangibles $24.92K $28.18K
YoY Change 5.72%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $53.70K $58.91K
YoY Change -9.61%
TOTAL ASSETS
Total Short-Term Assets $850.00 $1.862K
Total Long-Term Assets $53.70K $58.91K
Total Assets $54.55K $60.77K
YoY Change -7.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $1.113K $1.001K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $55.47K
YoY Change
Total Short-Term Liabilities $56.58K $56.47K
YoY Change 40.08%
LONG-TERM LIABILITIES
Long-Term Debt $12.50K
YoY Change
Other Long-Term Liabilities $25.50K
YoY Change
Total Long-Term Liabilities $38.00K $38.00K
YoY Change 49.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.58K $56.47K
Total Long-Term Liabilities $38.00K $38.00K
Total Liabilities $94.58K $94.47K
YoY Change 43.54%
SHAREHOLDERS EQUITY
Retained Earnings -$67.60K -$61.26K
YoY Change 9487.48%
Common Stock $667.00 $667.00
YoY Change 66.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$40.03K -$33.70K -$10.18K
YoY Change
Total Liabilities & Shareholders Equity $54.55K $60.77K
YoY Change -7.32%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q2
OPERATING ACTIVITIES
Net Income -$6.336K -$9.939K
YoY Change -36.25%
Depreciation, Depletion And Amortization $1.947K $1.947K
YoY Change 0.0%
Cash From Operating Activities -$1.012K -$3.500K
YoY Change -71.09%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 $3.500K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$1.012K -$3.500K
Cash From Investing Activities $0.00 $0.00
Cash From Financing Activities $0.00 $3.500K
Net Change In Cash -$1.012K $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$1.012K -$3.500K
Capital Expenditures $0.00
Free Cash Flow -$1.012K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001918694
CY2023Q2 dei Amendment Flag
AmendmentFlag
false
CY2023Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2023Q2 dei Document Type
DocumentType
10-Q
CY2023Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q2 dei Document Period End Date
DocumentPeriodEndDate
2023-05-31
CY2023Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 dei Entity File Number
EntityFileNumber
333-264308
CY2023Q2 dei Entity Registrant Name
EntityRegistrantName
MEDIES
CY2023Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2023Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1651594
CY2023Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Geng Road, Suite 210
CY2023Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
CY2023Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94303
CY2023Q2 dei City Area Code
CityAreaCode
650
CY2023Q2 dei Local Phone Number
LocalPhoneNumber
719-5286
CY2023Q2 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q2 dei Trading Symbol
TradingSymbol
MEDE
CY2023Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q2 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6666500 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
850 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1862 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
850 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1862 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24918 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28183 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28778 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30725 usd
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
53696 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
58908 usd
CY2023Q2 us-gaap Assets
Assets
54546 usd
CY2023Q1 us-gaap Assets
Assets
60770 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1113 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1001 usd
CY2023Q2 NONE Loans From Related Parties
LoansFromRelatedParties
55467 usd
CY2023Q1 NONE Loans From Related Parties
LoansFromRelatedParties
55467 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
56580 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
56468 usd
CY2023Q2 NONE Note Payable Related Party
NotePayableRelatedParty
12500 usd
CY2023Q1 NONE Note Payable Related Party
NotePayableRelatedParty
12500 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
25500 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
25500 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
38000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
38000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
94580 usd
CY2023Q1 us-gaap Liabilities
Liabilities
94468 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
667 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
667 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26899 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26899 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67600 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61264 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-40034 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-33698 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54546 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60770 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
695 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
0 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5469 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9939 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
6164 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9939 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
172 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
-0 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-172 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6336 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9939 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6336 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9939 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6666500 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6666500 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4000000 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-33698 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6336 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-40034 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-239 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9939 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-10178 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6336 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9939 usd
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3265 usd
CY2022Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
2223 usd
CY2023Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2022Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2023Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
112 usd
CY2022Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2269 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1012 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3500 usd
CY2023Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
CY2022Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2022Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
3500 usd
CY2023Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2022Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3500 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1012 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1862 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
400 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
850 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
400 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q2 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q2 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_zlZzYATU71R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zGoAYbokbWok">Use of Estimates and Assumptions</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the limited level of operations, the Company has not had to make material assumptions or estimates other than the assumption that the Company is a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2023Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38930 usd
CY2023Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2023Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2022Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10152 usd
CY2023Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3265 usd
CY2022Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
2223 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14262 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2023 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
4607 usd
CY2023Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1331 usd
CY2022Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
12655 usd
CY2023Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1331 usd
CY2022Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-12655 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1331 usd
CY2023Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12655 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1331 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12655 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
67600 usd

Files In Submission

Name View Source Status
0001683168-23-004915-index-headers.html Edgar Link pending
0001683168-23-004915-index.html Edgar Link pending
0001683168-23-004915.txt Edgar Link pending
0001683168-23-004915-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
medies_ex3101.htm Edgar Link pending
medies_ex3102.htm Edgar Link pending
medies_ex3201.htm Edgar Link pending
medies_ex3202.htm Edgar Link pending
medies_i10q-053123.htm Edgar Link pending
MetaLinks.json Edgar Link pending
none-20230531.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
none-20230531_cal.xml Edgar Link unprocessable
none-20230531_def.xml Edgar Link unprocessable
none-20230531_lab.xml Edgar Link unprocessable
none-20230531_pre.xml Edgar Link unprocessable
medies_i10q-053123_htm.xml Edgar Link completed